A phase 2, open-label, single-arm trial (ATLANTIC) studied the efficacy of durvalumab, a PD-L1 inhibitor, in pretreated NSCLC including 111 patients with EGFR or ALK alteration [26•]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.